Brokerage firm Stifel Nicolaus Maintains its rating on GlycoMimetics Inc(NASDAQ:GLYC). In a research note issued to the investors, the brokerage major Raises the price-target to $15.00 per share. The shares have been rated Buy. The rating by Stifel Nicolaus was issued on Aug 5, 2016.
In a different note, SunTrust Robinson Humphrey said it Initiates Coverage on GlycoMimetics Inc, according to a research note issued on Jul 26, 2016. The shares have been rated ‘Buy’ by the firm.
GlycoMimetics Inc (GLYC) made into the market gainers list on Wednesdays trading session with the shares advancing 0.13% or 0.01 points. Due to strong positive momentum, the stock ended at $7.98, which is also near the day’s high of $8.14. The stock began the session at $8 and the volume stood at 14,681 shares. The 52-week high of the shares is $9.25 and the 52 week low is $3.7. The company has a current market capitalization of $184 M and it has 2,30,56,277 shares in outstanding.
GlycoMimetics Inc(GLYC) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.41. Analysts had estimated an EPS of $-0.45.
Several Insider Transactions has been reported to the SEC. On Jul 6, 2016, Helen M. Thackray (VP Clinical Development, CMO) sold 22,000 shares at $7.03 per share price.Also, On Mar 7, 2016, Mark Alan Goldberg (director) purchased 10,397 shares at $4.77 per share price.On Nov 18, 2015, Peter J Barris (10% owner) sold 452 shares at $6.91 per share price, according to the Form-4 filing with the securities and exchange commission.
GlycoMimetics Inc. (GlycoMimetics) is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs to address medical needs. The Company’s pipeline includes GMI-1070 (Rivipansel) GMI-1271 GMI-1359 (E-selectin and CXCR4 antagonist) GMI-1051 and Galectin inhibitors. The Company developing rivipansel to treat VOC (vaso-occlusive crisis) with the goal of reducing duration of VOC episodes length of hospital stay and use of opioid analgesics for pain management. The Company is developing GMI-1271 a specific E-selectin antagonist to be used in combination with chemotherapy to treat AML (acute myeloid leukemia) and other hematologic cancers. GMI-1359 simultaneously inhibits both E-selectin and CXCR4 for use in the treatment of cancers with bone marrow involvement such as myeloma. GMI-1051 is an antagonist of two pseudomonas virulence factors PA-IL and PA-IIL.